复发难治外周T细胞淋巴瘤治疗进展  

Treatment progress of relapsed/refractory peripheral T-cell lymphoma

作　　者：邓吉利 张晨[1] 宋玉琴[1] Deng Jili;Zhang Chen;Song Yuqin(Department of Lymphoma,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《白血病．淋巴瘤》2023年第1期18-21,共4页Journal of Leukemia & Lymphoma

摘　　要：外周T细胞淋巴瘤(PTCL)是一组高度异质性疾病,亚型多,整体预后差,复发难治患者尤为如此,且患者普遍年龄较大,能够耐受的治疗选择有限。2022年第64届美国血液学会(ASH)年会关于复发难治PTCL的研究包括表观遗传学药物的联用或联合免疫检查点抑制剂、CD30抗体耦联药物(ADC)维布妥昔单抗联合化疗、靶向药物PI3K抑制剂及JAK1抑制剂等,为复发难治患者提供了更多选择与机会。Peripheral T-cell lymphoma(PTCL)is a highly heterogeneous disease with numerous subtypes,and the overall prognosis is poor,especially in relapsed/refractory patients,and the patients are generally older with limited treatment options that can be tolerated.At the 64th American Society of Hematology(ASH)Annual Meeting in 2022,studies on relapsed/refractory PTCL include the combination of epigenetic agents or combination of immune checkpoint inhibitors,CD30 antibody-drug conjugate(ADC)brentuximab vedotin combined with chemotherapy,targeted drugs PI3K inhibitors and JAK1 inhibitors,etc.,providing more choices and opportunities for relapsed/refractory patients.

关 键 词：淋巴瘤 外周T细胞 复发 难治 治疗 

分 类 号：R733.1[医药卫生—肿瘤]